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A candidate gene approach to identifying novel causes of disease is concept-limiting and in the new era of
high throughput sequencing there is now no need to restrict the experiment to a few interesting genes. We
have recently completed a large-scale exon re-sequencing project using Sanger sequencing technology to
analyse approximately 1 Mb of coding sequence of the X chromosome in probands from >200 families
with various forms of intellectual disability. We review the lessons learnt from this experience. Comparing
large data sets will certainly reveal pathogenic mutations in genes that were not possible to identify pre-
viously. However, the task of distinguishing pathogenic mutations from rare sequence variants is not easy
and is the most substantial challenge to the next decade. High-throughput technology has the attraction
of being cheap, fast and comprehensive but for projects that require detailed coverage of a genomic
region at an exhaustive level they may require a combination of large-scale with a small-scale follow-up of
difﬁcult regions to sequence. The number of rare truncating variants present in coding regions of the X
chromosome that are not pathogenic was 1%. The importance of the quality of the starting material both clini-
cally and molecularly and the number of sequence variants both rare and common that any one individual
has across their coding sequence is discussed.
INTRODUCTION
We have recently published the results of a large-scale exon
re-sequencing project to identify the cause of disease (1).
This is the ﬁrst of its kind where approximately 1 Mb of
coding sequence of the X chromosome has been analysed in
probands from .200 families with various forms of intellec-
tual disability. While this is a considerable achievement with
the current Sanger technology, this merely acts as a pilot
study for the analyses of whole genomes in cohorts of individ-
uals in the near future. The advent and ever increasing pre-
sence of the next-generation sequencing technology has
fuelled an increase in large-scale sequencing projects and is
heralding in the era of personalised genomes. Recently, the
1000 genome project has been launched (http://www.
1000genomes.org) and in a few years the identiﬁcation
of the complete genomic sequence of an individual will be
commonplace and will neither be limited by cost nor by tech-
nical expertise (2,3). We anticipate, however, that the
interpretation of the data will become the central issue and
concern, as it is not trivial. Having completed our study, it
seems timely to review the lessons learnt from this experience,
and to anticipate where the key challenges may lie in the
future.
In our view, the overall strategy has been highly successful
in the identiﬁcation of novel X-linked genes that cause mono-
genic disease. This project has identiﬁed 12 new X-linked
mental retardation (XLMR) genes that were not previously
described and has also contributed to the discovery of four
other genes (1,4–17). We also trust that several further
XLMR genes are yet to be mined from the data. There is no
doubt that this type of project is both feasible, achievable
and a way forward to understand diseases that are genetically
heterogenous (18,19).
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Epidemiological and genetic data for XLMR suggested that
many genes were likely to cause the disease but individually
the gene is a rare cause of disease although fully penetrant.
While the positional and candidate gene-screening identiﬁed
many XLMR genes, a new systematic approach was needed
in order to identify the remainder (20).
As there were many potential disease genes to interrogate
(.700 on the X chromosome), a rapid high-throughput gene
abnormality detection methodology was needed. Also, the
mutation detection method had to be accurate and not miss
real but rare sequence variants (RSVs). For this reason, a
direct polymerase chain reaction (PCR)-based DNA-
sequencing method was chosen which used Sanger-based ﬂu-
orescent sequence analysis rather than pre-screening samples
with heteroduplex analysis or similar screening protocols.
This particular project also gained from the hemizygous
nature of the X chromosome in males such that mutation detec-
tion was always homozygous and relatively easy to identify.
In addition, large amounts of starting material was needed
so that the availability of DNA was not rate-limiting. At the
time we began, lymphoblastoid cell lines were created from
most probands in the study so that high-quality DNA was
available. DNA from low passage numbers was used to
reduce the error rate from sequence alterations and chromoso-
mal loss because of EBV transformation (21,22). Paired DNA
samples from untransformed cells were always retained so that
positive ﬁndings from the cell line DNA were always veriﬁed
in the original DNA sample from blood. With the availability
of accurate whole genome ampliﬁcation protocols, it may no
longer be necessary to create lymphoblastoid cell lines.
However, the quality of the starting DNA material is critical.
In our experience, old and poorly stored DNA samples often
yield false-positive sequence abnormalities in high-throughput
sequencing because of degradation of the DNA and whole
genome ampliﬁcation does not rectify this. In our study,
several families were removed from further analysis as the
number of missense mutations throughout the X chromosome
were so high, .25, and were not reproducible in a second
sample from the original stock. It was assumed that these
were owing to poor quality starting DNA material. For the
whole genome-ampliﬁed DNA, there was a close correlation
between poor performance of the sample which we used, the
age of the original sample and the amount of the remaining
starting material.
As each gene was likely to be rare, we ensured that the hit
rate for any one gene was maximized by starting with DNA
from a large number of families with good evidence of
X-linkage. As the disease is so highly heterogeneous,
pooling of sample data was not feasible and thus by its very
nature, this project required a large international collaboration
between clinicians and molecular geneticists (the IGOLD
project; http://goldstudy.cimr.cam.ac.uk/). This has been
invaluable and has ensured that the sample selected for
sequencing was derived from a larger cohort that could be
reﬁned. Families were selected out of a possible cohort of
.600 families, where the evidence of an X-linked monogenic
disease was greatest, there were high-quality DNA samples
available and where a pathogenic mutation in a known MR
gene had been excluded or the clinical picture was not
typical of a syndrome where the causative gene had already
been determined, e.g Cofﬁn Lowry syndrome. All subjects
were pre-screened clinically by an experienced clinical geneti-
cist, a recent karyotype analysis was normal at a 500G level
and Fragile X syndrome was excluded molecularly. This
meant that the clinical data were of high quality and the
samples were enriched for families, where a novel disease-
causing gene was likely to be present but it created ascertain-
ment biases that precluded any meaningful prevalence assess-
ment of any new gene when it emerged in the context of
XLMR as a whole. The strategy did, however, enable
several new syndromes to be deﬁned from the cohort once
we had obtained the sequencing results (CUL4B, SLC9A6,
MED12).
Careful assessment of the pathogenic signiﬁcance of a
sequence variant in this project has been a primary aim as
the degree of coding sequence variation over a large number
of genes from any one individual was not known. In order
to do this, having sufﬁcient samples from appropriate controls
was important and in some cases over 1000 controls were ana-
lysed to identify the frequency of RSVs in each gene. Also, we
used detailed segregation analysis in families to assess a puta-
tive pathogenic sequence variant. This enabled a number of
sequence variants to be deﬁnitively excluded because of non-
segregation of the variant with disease.
TECHNICAL CHALLENGES
One of the major advantages of high-throughput method-
ologies is their unbiased nature. The ﬁeld of XLMR gene dis-
covery was previously subject to various biases including
small sets of families and the use of candidate gene selection
criteria. This project aimed to interrogate all or as many as
possible of the 720 VEGA-annotated genes on the X chromo-
some using unique sequence primer design. Only regions of
intra- or inter-chromosomal similarity were not interrogated,
which was only a signiﬁcant problem for the X-Y pseudoauto-
somal region of the X.
In addition, a high-throughput method requires a simple
experimental protocol in order to maximize speed and efﬁ-
ciency. This means that both automated primer design and
relatively inﬂexible PCR protocols are required with the inevi-
table associated reduction of coverage for each gene compared
with gene-speciﬁc protocols. Although the data set reported on
the families in the cohort included sequence analysis of  75%
of all exons on the X chromosome, the high-throughput analy-
sis is not necessarily complete for all genes. The coverage was
biased according to GC content, such that exon 1 was rela-
tively poorly represented in all genes and some genes with a
high overall GC content, e.g. ARX were particularly poorly
sequenced.
We used high-throughput sequence analysis in order to
detect new genes that cause disease as we predicted that the
greatest number of disease-causing mutations were small
sequence variants that could be detected by this method. In
principle, this methodology would technically also detect
whole exon deletions because of failure to amplify a PCR
product, but in practice this was not analysed extensively, as
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ampliﬁcation was frequently the cause of failure to amplify
rather the presence of a deletion. On completion of the
sequence analysis we found that 16% of the cohort did not
have any unique missense variant detected at all. As many
of the families with no signiﬁcant sequence variant detected
are multigenerational families with a high likelihood of
having a single pathogenic mutation, additional methods
such as array CGH are now being used to systematically ident-
ify whole exon deletions and duplications as a cause of
disease.
Data handling is a major issue in this type of project,
manual inspection of all the traces was not possible as .3
million traces were generated. However, the commercially
available sequence trace analysis packages were not sufﬁ-
ciently robust to interpret the abnormal traces they detected
and a degree of manual inspection was needed to assess
traces where sequence variants were detected in both
sequencing directions (23). The data analysis required the
expertise of a genome centre (http://www.sanger.ac.uk)
where in-house bioinformaticians could develop the analysis
programmes and where there was sufﬁcient capacity to store
these large data sets, and also, where people were available
to be deployed to inspect the abnormal sequence traces for a
period of time in the project.
In large cohort studies the potential to generate huge
amounts of data is unquestionable. The issue of how this
should be made available to the scientiﬁc community is a
little more complex. For families who took part in our study,
the commonest reasons for taking part was their desire to
know what the genetic cause of the disease was in their
family, they wanted to know if others in the family were at
risk of having children with a similar condition and also,
they wanted to contribute to the overall knowledge of learning
disability to improve diagnoses for families in general (24). In
this study, the data set for each family effectively provides a
series of unique identiﬁers for each patient on the X chromo-
some. This creates a tension between the need for the scientiﬁc
community to have access to large scale data sets of sequence
and the need to preserve conﬁdentiality of all patients taking
part in a study. This is a relatively new situation and while par-
ticipants consented to take part in the study they did not expli-
citly consent for their personal genotype to be placed on the
internet for all to see. We have thus limited access to the
data of researchers who participate in the general academic
peer review publication process as a means of ensuring that
the data set is used for scientiﬁc and medical beneﬁt and
thus conforms to the consent but we also hope that the data
will be used by the scientiﬁc community as much as possible
in order to support the aims of publicly funded research (http://
goldstudy.cimr.cam.ac.uk/).
INTERPRETIVE CHALLENGES
Assigning a gene to a disease is relatively straightforward
where the phenotype is clear and the disease is predominantly
because of truncating mutations in a single gene. This proved
to be the case for FRMD7, where most cases of X-linked con-
genital nystagmus were owing to truncating mutations in the
single novel gene we identiﬁed (5). However, for clinically
more heterogenous conditions such as XLMR the criteria
used to judge whether or not a sequence variant is the cause
of disease needs more careful analysis. For recessive diseases,
the identiﬁcation of a truncating or loss of function variant is
likely to cause disease, however, in genes where there is no
prior evidence of variants causing disease, the presence of a
truncating variant in a single family where the disease is het-
erogenous is probably not sufﬁcient. We identiﬁed seven
XLMR genes, where we were able to detect multiple truncat-
ing variants in the gene and yet found no truncating variants in
a large control set that were fully sequenced for the gene in
question. However, we identiﬁed a further 19 genes where a
single truncating variant was identiﬁed in the disease group.
Many of these rare variants were then excluded by segregation
analysis or more extensive analysis of a control population.
Without the extended pedigrees we would not have been
able to exclude so many of these genes. This suggests that
up to 1% of the genes on the X chromosome can sustain
loss-of-function variants and they do not appear to have a det-
rimental effect. It is likely that a similar proportion of genes on
autosomes are potentially redundant although the proportion
of redundant genes on the X chromosome may be greater
than for autosomes (25–27). We believe that the identiﬁcation
of a single rare deletion of a gene or part of a gene or a
truncating variant is not sufﬁcient evidence that the gene
abnormality is pathogenic and without the assistance of
parental samples and extended pedigrees this can be difﬁcult
to interpret.
Because the sequencing analysis covered all coding exons
on the X chromosome, this project acts as a screen shot of
the human genome at a speciﬁc moment in the evolutionary
continuum of the X chromosome. Provided there were
deﬁned exons on a genome browser an amplicon was investi-
gated. The genome browsers make little distinctions between
coding and non-coding parts of exons, nor pseudogenes or
transposons or genome sequences that are travelling between
these states by natural selection (25–28). The signiﬁcance of
a sequence variant will depend on the location of the variant
within the sequence, the background polymorphism rate of
the gene and the functional redundancy of the protein in the
organism. Although prediction programmes like Polyphen,
Panther and SIFT, and measures of protein evolution are
useful in assessing whether a variant is likely to be pathogenic,
the current tools available to determine pathogenicity are
limited (29,30).
In the ﬁrst analysis of the data we were surprised not to
identify more truncating mutations in genes than we did (38/
208). As most of the XLMR genes that had been identiﬁed
prior to the project starting contained truncating mutations
as the predominant disease-causing class of mutation, we
assumed that this would continue in the cohort we analysed
looking for novel genes that cause mental retardation. There
are, however, precedents for genes on the X chromosome
where truncating mutations are likely to be lethal such as
MECP2, NEMO, CDKL5 and more recently CASK and this
may explain why very few families were explained by a trun-
cating mutation (1,31–34). It also seems possible that the pre-
vious XLMR studies were biased towards identifying the
protein truncating variants and only the difﬁculty to ﬁnd
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truncating variants were missed by the high-throughput strat-
egy as only 75% of the X chromosome was covered on
average per family and thus 25% of mutations would have
been missed.
Perhaps, the most surprising feature of the data set is the
number of rare coding sequence variants that were identiﬁed
in any one individual. The project was focused on the
coding sequence of the X chromosome, an area of the
genome, where fewer sequence variants are found compared
with non-coding regions. Nevertheless, for any one individual
we identiﬁed on average three to four unique amino acid
sequence changes over and above the expected high number
of common non-synonymous and synonymous coding poly-
morphisms. Perhaps, it was naı ¨ve to imagine that for each
family we studied with mental retardation, a single pathogenic
variant would be identiﬁed as the cause of the disease as on
average .5000 exons were sequenced in any one individual.
Of the unique sequence variants we identiﬁed, the majority are
likely not to be the cause of the mental retardation phenotype
in the patients as the pedigree structure suggests that the
disease is likely to be owing to a single gene defect. Techni-
cally, the other unique sequence variants found in an individ-
ual are not classed as polymorphisms as they are less frequent
than 1% of the population. We have termed these RSVs. The
problem is the difﬁculty in establishing in any one individual
the sequence changes that are pathogenic and cause mental
retardation and which are RSVs of no pathogenic signiﬁcance
or of signiﬁcance to the individual but not contributing to the
MR phenotype. For some, assigning pathogenicity may be
easier as the variant occurs in highly conserved residues in
an active site of a protein or in a protein known to be involved
in syndromic mental retardation or it can be dismissed as the
RSV does not segregate with disease in the family. However,
where two RSVs are in linkage disequilibrium or within
neighbouring genes it is unlikely that segregation analysis
will resolve the issue of pathogenicity. Currently, there
are few resources available to identify whether the rare
variants have been identiﬁed elsewhere before. The HapMap
project (http://www.hapmap.org/) and other SNP identiﬁcation
resources such as dbSNP (http://www.ncbi.nlm.nih.gov/SNP),
all concentrate on the common alleles in the population and do
not report RSVs routinely. For many of the RSVs, we ident-
iﬁed that a bioinformatic approach alone is insufﬁcient to
determine pathogenicity and a detailed assessment of the func-
tional consequence of each sequence variant is needed. In
practice, no high throughput or even medium throughput
methodology has been developed for this and this is now the
rate-limiting step in the identiﬁcation of further genes that
cause disease.
SUMMARY
A candidate gene approach to identifying novel causes of
disease is concept-limiting and in the new era of next gener-
ation sequencing there is no need to restrict the experiment
to a few interesting genes. We are entering a data-rich
period where more and more sequence analysis is possible.
Comparing large data sets will reveal genetic pathology that
was not possible to identify previously. However, the task of
distinguishing pathogenic mutations from RSVs is not
resolved and is perhaps the most substantial challenge to the
next decade. High-throughput technology has the attraction
of being new and big but the failing of lack of adaptability
means that projects that require detailed coverage of a candi-
date region at an exhaustive level may require a combination
of large-scale with a small-scale follow-up of difﬁcult regions
to sequence. The number of rare truncating variants present in
the genome that are not pathogenic was a surprise. Until we
came to the ﬁnal analysis we had not appreciated the import-
ance of the quality of the starting material both clinically and
molecularly, how to release the data to maintain the best inter-
ests of all parties involved and the sheer number of sequence
variants any one individual has across their coding sequence.
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